Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 145.06

+0.7%

1:20 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (770)	7/17/2001 9:56:28 PM
From: Biotech Jim	Read Replies (3) of 1834

Wilder- Thanks for the complete notes from the conference call. Things appear to be very thorough to me, being performed by NBIX's "Dream Team." I was unable to listen in on the CC. I'm interested to hear if anything more was mentioned concerning the topic: "TAK’s melanacortin analogue"? Also, Do you have information on the age groups tested in the studies? Thanks for you continuing efforts in this and related threads. BTW, The NeuroInvestment newsletter has a $60 price target, as per the June, 2001 issue # 72. My three year target (July, 2004) is $150, about a $4B market cap, assuming approval of the GABAergic sedation compound, and a CRF1 antagonist in Ph 2 studies with documentation of safety and efficacy. The other programs would be gravy. Disclosure: I've been holding NBIX since 11/00, and trade it from time to time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next